2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T6f3f,

Summary Table

Category	Details
Risk Factors	Age > 50 years, male sex, family history of Lewy body dementia or Parkinson disease, REM sleep behavior disorder preceding cognitive decline
Etiology	Abnormal aggregation of alpha-synuclein protein forming Lewy bodies in cortical and subcortical neurons
Patient Presentation	Progressive cognitive decline with prominent deficits in attention, executive function, and visuospatial ability (memory may be relatively preserved early on)
Classic Physical Exam	Fluctuating cognition (episodes of "staring into space" or drowsiness alternating with lucidity), recurrent well-formed visual hallucinations, spontaneous parkinsonism (rigidity, bradykinesia, shuffling gait, but resting tremor is less prominent than in Parkinson disease)
Key Diagnostic Results	Clinical diagnosis using consensus criteria; DaTscan showing reduced dopamine transporter uptake in basal ganglia; polysomnography confirming REM sleep behavior disorder (RBD); relative preservation of hippocampal and medial temporal lobe volume on MRI (unlike Alzheimer disease)
Management	Cholinesterase inhibitors (rivastigmine preferred); AVOID antipsychotics (severe neuroleptic sensitivity); low-dose carbidopa-levodopa for motor symptoms; melatonin or low-dose clonazepam for RBD
Keywords	"Fluctuating alertness," "well-formed visual hallucinations," "sees people or animals that aren't there," "acts out dreams," "sensitive to haloperidol," "worsened by antipsychotics," "Parkinson-plus dementia"

1. Pathophysiology

Lewy body dementia arises from the abnormal intracellular accumulation of alpha-synuclein, a presynaptic protein that misfolds and aggregates into spherical cytoplasmic inclusions called Lewy bodies. These inclusions are also found in Parkinson disease, which is why both conditions belong to the synucleinopathy spectrum. The fundamental difference lies in the distribution: in Lewy body dementia, Lewy bodies deposit widely throughout the cerebral cortex (especially the temporal, parietal, and cingulate cortices) in addition to subcortical structures, whereas in Parkinson disease, the pathology initially concentrates in the substantia nigra.

The cortical Lewy body burden explains why cognition is affected early and prominently. Disruption of cortical cholinergic circuits (originating from the nucleus basalis of Meynert) leads to profound cholinergic deficits, which are actually more severe than those seen in Alzheimer disease. This cholinergic loss drives the fluctuating attention and alertness that define the disease; caregivers often describe the patient as having "good days and bad days" or episodic confusion alternating with near-normal function.

The visual hallucinations are characteristically well-formed and detailed (the patient describes seeing children, animals, or intruders). These arise from Lewy body deposition in the visual association cortex (occipital and parieto-occipital regions), disrupting visual processing while primary visual acuity may remain intact. This cortical visual dysfunction also explains the early and disproportionate visuospatial impairment, which is a distinguishing feature from Alzheimer disease, where memory loss dominates.

Parkinsonism results from concurrent Lewy body accumulation in the substantia nigra, producing dopaminergic neuron loss. However, the motor features tend to be more symmetric and rigidity-predominant, with less prominent resting tremor compared to idiopathic Parkinson disease.

The extreme neuroleptic sensitivity is a critical teaching point. Because dopaminergic pathways are already compromised, administering a dopamine receptor blocker (such as haloperidol or other typical antipsychotics) can precipitate a catastrophic reaction: severe rigidity, obtundation, autonomic instability resembling neuroleptic malignant syndrome, and even death. This vulnerability stems from the already depleted dopamine reserve in these patients.

REM sleep behavior disorder (loss of normal skeletal muscle atonia during REM sleep, causing the patient to physically act out dreams) results from brainstem Lewy body pathology affecting the pontine tegmentum and sublaterodorsal nucleus. Importantly, RBD may precede the cognitive and motor symptoms by years to decades, making it a prodromal marker of synucleinopathy.

2. Classification and Clinical Manifestation

The current consensus criteria classify clinical features into core, suggestive, and supportive categories. Diagnosis requires dementia plus a combination of these features.

Core Clinical Features

Feature	Description
Fluctuating cognition	Spontaneous variations in attention and alertness; episodes of staring, disorganized speech, or drowsiness interspersed with periods of near-normal function
Recurrent visual hallucinations	Well-formed, detailed, often of people or animals; typically not distressing early in the disease; the patient may have partial insight initially
REM sleep behavior disorder	Loss of REM atonia; patient kicks, punches, screams, or falls out of bed while dreaming; bed partner often provides the history
Spontaneous parkinsonism	Bradykinesia, rigidity, and/or postural instability; resting tremor is less common than in Parkinson disease; onset must follow or coincide with cognitive decline

Suggestive and Supportive Features

Category	Features
Suggestive features	Severe neuroleptic sensitivity, reduced dopamine transporter uptake on DaTscan/SPECT, RBD confirmed on polysomnography
Supportive clinical features	Repeated falls, syncope, transient unexplained loss of consciousness, severe autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation), hypersomnia, hyposmia, delusions, apathy, anxiety, depression
Supportive biomarkers	Relative preservation of medial temporal lobe on MRI, low occipital uptake on PET perfusion/metabolism scans, prominent posterior slow-wave EEG activity with periodic fluctuations in the pre-alpha/theta range, reduced MIBG uptake on myocardial scintigraphy

Diagnostic Probability

Classification	Criteria Required
Probable Lewy body dementia	Dementia plus two or more core features, OR dementia plus one core feature and one or more suggestive features
Possible Lewy body dementia	Dementia plus only one core feature (without suggestive features), OR dementia plus one or more suggestive features only

The "One-Year Rule"

Condition	Temporal Relationship
Lewy body dementia	Cognitive symptoms develop before, concurrently with, or within one year of parkinsonism
Parkinson disease dementia	Dementia develops more than one year after the onset of well-established Parkinson motor symptoms

This distinction is somewhat arbitrary and reflects a shared pathological spectrum, but it is consistently tested and you should know it for the exam.

3. Diagnostic Workup

Test	Role	Key Findings
Clinical assessment	Best initial approach	Fluctuating cognition, visual hallucinations, parkinsonism, RBD; use standardized cognitive tools focusing on attention and visuospatial function
DaTscan (FP-CIT SPECT)	Suggestive biomarker; differentiates from Alzheimer disease	Reduced dopamine transporter uptake in caudate and putamen
Polysomnography	Confirms RBD	REM sleep without atonia (elevated chin EMG tone or excessive limb movements during REM)
MRI brain	Supportive; excludes structural causes	Relative preservation of hippocampal and medial temporal lobe volume (unlike Alzheimer disease); may show generalized atrophy
FDG-PET or SPECT perfusion	Supportive biomarker	Occipital hypometabolism/hypoperfusion (the "cingulate island sign" on FDG-PET may also be seen)
MIBG myocardial scintigraphy	Suggestive biomarker (reflects cardiac sympathetic denervation)	Reduced cardiac MIBG uptake
EEG	Supportive	Prominent posterior slow-wave activity with periodic fluctuations
Neuropathology (autopsy)	Gold standard / most accurate	Cortical and subcortical Lewy bodies (alpha-synuclein positive inclusions)

The diagnosis of Lewy body dementia is fundamentally clinical. There is no single blood test or imaging study that confirms it during life. When a vignette describes an elderly patient with progressive cognitive decline characterized by fluctuating attention, well-formed visual hallucinations, and parkinsonism, you should already be thinking of this diagnosis before any tests are ordered.

The best initial step is a thorough history (often from a caregiver who can describe the fluctuations and nocturnal behaviors) combined with a focused neurological and cognitive examination. Standard cognitive screening tools like the MMSE or MoCA will show deficits, but visuospatial tasks (clock drawing, copying intersecting pentagons) are disproportionately impaired relative to memory performance, which helps differentiate from Alzheimer disease early in the course.

DaTscan (dopamine transporter SPECT) is the most clinically useful confirmatory imaging study during life. It shows reduced uptake in the striatum (caudate and putamen), reflecting nigrostriatal dopaminergic degeneration. This finding is not present in Alzheimer disease, making DaTscan a powerful differentiator. On exam, if a question asks "which test best distinguishes Lewy body dementia from Alzheimer disease," the answer is DaTscan.

Polysomnography is ordered when RBD is suspected but not witnessed clearly. It objectively demonstrates REM sleep without atonia, which is both a core feature and a prodromal biomarker.

Brain MRI is essential to exclude other causes of dementia (stroke, normal pressure hydrocephalus, tumors) but also provides a supportive clue: the medial temporal lobes and hippocampi are relatively preserved in Lewy body dementia compared to the characteristic hippocampal atrophy of Alzheimer disease.

FDG-PET may show occipital hypometabolism, which is relatively unique to Lewy body dementia and reflects the posterior cortical involvement that drives the visual hallucinations and visuospatial deficits.

The gold standard remains neuropathological examination at autopsy showing cortical Lewy bodies immunoreactive for alpha-synuclein. This is not clinically actionable during life but may appear as the "most accurate test" in a question stem.

4. Management and Treatment

Domain	Intervention	Details
Cognitive symptoms	Rivastigmine (first-line cholinesterase inhibitor)	Start 1.5 mg PO twice daily; titrate every 2 weeks up to 6 mg twice daily (or use transdermal patch: start 4.6 mg/24h, titrate to 9.5 or 13.3 mg/24h)
Cognitive symptoms (alternative)	Donepezil or galantamine	Donepezil 5 to 10 mg PO once daily; galantamine 4 mg twice daily titrated to 12 mg twice daily
Visual hallucinations	Low-dose quetiapine or pimavanserin	Quetiapine 12.5 to 50 mg at bedtime; pimavanserin 34 mg daily (FDA-approved for Parkinson disease psychosis; used off-label in Lewy body dementia)
AVOID	Typical antipsychotics, high-potency D2 blockers	Haloperidol and other typical agents are contraindicated; can cause irreversible parkinsonism, rigidity, autonomic crisis, or death
Parkinsonism	Low-dose carbidopa-levodopa	Start at the lowest effective dose; titrate cautiously because levodopa can worsen hallucinations and psychosis
REM sleep behavior disorder	Melatonin (first-line), clonazepam (second-line)	Melatonin 3 to 12 mg at bedtime; clonazepam 0.25 to 0.5 mg at bedtime (use cautiously in elderly due to fall risk and respiratory depression)
Depression	SSRIs	Sertraline or citalopram at standard doses; avoid tricyclics due to anticholinergic burden
Autonomic dysfunction	Symptomatic management	Midodrine or fludrocortisone for orthostatic hypotension; dietary fiber and osmotic laxatives for constipation
Non-pharmacologic	Environmental and caregiver-based	Consistent routines, adequate lighting to reduce hallucinations, physical therapy for mobility, caregiver education about fluctuations

Cholinesterase inhibitors are the cornerstone of treatment. The rationale is straightforward: Lewy body dementia produces a more severe cholinergic deficit than Alzheimer disease, which means these patients often respond more robustly to cholinesterase inhibitors. Rivastigmine has the strongest evidence base and is generally considered first-line. It improves cognition, attention, behavioral symptoms, and may even reduce hallucinations. Donepezil and galantamine are reasonable alternatives. The transdermal rivastigmine patch is preferred in patients with gastrointestinal intolerance.

The most critical management principle for exams is: never give typical antipsychotics. When a vignette describes a demented patient with hallucinations and the question offers haloperidol as a treatment option, you must recognize the trap. In Lewy body dementia, administering a dopamine D2 receptor antagonist (especially high-potency agents like haloperidol) can trigger a life-threatening neuroleptic sensitivity reaction with severe rigidity, altered consciousness, autonomic instability, and potentially death. Even atypical antipsychotics must be used with extreme caution. If antipsychotic treatment is absolutely necessary for disabling or dangerous psychosis, quetiapine (which has the weakest D2 binding among atypical agents) is the safest option at the lowest possible dose. Pimavanserin, a selective serotonin 5-HT2A inverse agonist with no dopaminergic activity, is an emerging option.

For motor symptoms, carbidopa-levodopa is used cautiously. The therapeutic window is narrow because levodopa can improve rigidity and bradykinesia but simultaneously worsen hallucinations and psychosis. Start at the lowest dose and titrate slowly. Dopamine agonists (pramipexole, ropinirole) are generally avoided because they carry a higher risk of exacerbating psychosis compared to levodopa.

REM sleep behavior disorder should be addressed both for the patient's safety and the bed partner's. Melatonin is preferred as first-line because it is well-tolerated and carries minimal risk. Clonazepam is effective but should be used judiciously in elderly patients because of sedation, cognitive worsening, and fall risk. Environmental safety measures (padding around the bed, removing sharp objects from the bedroom, sleeping in a separate bed if needed) are also important.

There is no disease-modifying therapy available. Management is entirely symptomatic and supportive. Prognosis is generally worse than Alzheimer disease, with a median survival of approximately 5 to 8 years from diagnosis.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Alzheimer disease	Both present with progressive dementia in the elderly; both can eventually develop behavioral symptoms and psychosis	Alzheimer disease presents with early and prominent memory loss (hippocampal atrophy on MRI); Lewy body dementia presents with early visuospatial and attentional deficits, fluctuations, visual hallucinations, and parkinsonism; hippocampi are relatively preserved in Lewy body dementia
Parkinson disease dementia	Identical pathology (Lewy bodies); both have parkinsonism, cognitive decline, hallucinations, and RBD	The temporal sequence distinguishes them: in Parkinson disease dementia, well-established motor symptoms precede dementia by more than one year; in Lewy body dementia, cognitive symptoms come first or appear within one year of motor onset
Vascular dementia	Both can present with fluctuating cognition, gait abnormalities, and executive dysfunction	Vascular dementia shows stepwise decline correlated with cerebrovascular events; MRI reveals white matter lesions, lacunar infarcts, or strategic infarcts; no visual hallucinations or RBD
Delirium	The fluctuating alertness and visual hallucinations of Lewy body dementia can mimic delirium	Delirium has an acute onset with an identifiable precipitant (infection, medication, metabolic derangement); Lewy body dementia has a chronic, progressive course with fluctuations that recur over weeks to months without a clear trigger
Frontotemporal dementia (behavioral variant)	Both can present with personality changes, behavioral disturbance, and executive dysfunction	Frontotemporal dementia presents with prominent personality change, disinhibition, apathy, and language decline at a younger age (50s to 60s); no parkinsonism, no visual hallucinations, no RBD; frontal and temporal atrophy on imaging
Normal pressure hydrocephalus	Both present with gait disturbance, cognitive impairment, and may have urinary incontinence	Normal pressure hydrocephalus shows the classic triad of wet, wobbly, and wacky (urinary incontinence, gait apraxia, dementia); MRI shows ventricular enlargement out of proportion to sulcal atrophy; no hallucinations or RBD; improves with CSF drainage
Creutzfeldt-Jakob disease	Both can present with rapidly progressive dementia, myoclonus, and visual symptoms	Creutzfeldt-Jakob disease is rapidly progressive (weeks to months, not years); shows periodic sharp-wave complexes on EEG, cortical ribboning and DWI restriction on MRI, and elevated 14-3-3 protein and RT-QuIC in CSF

6. Traps and High-Yield Pearls

The single most common way students get Lewy body dementia questions wrong is by failing to recognize the diagnosis and then selecting an antipsychotic for the hallucinations. The classic exam trap works like this: the vignette describes an elderly patient with progressive cognitive decline and vivid visual hallucinations. A student who does not notice the clues for Lewy body dementia (fluctuating alertness, parkinsonism, RBD mentioned in passing) may diagnose "dementia with psychosis" and choose haloperidol. This is the wrong answer and reflects the most dangerous clinical mistake you can make in this disease. The correct answer is almost always a cholinesterase inhibitor (rivastigmine) as first-line, or quetiapine if psychosis is severe and disabling.

A second common trap involves confusing Lewy body dementia with delirium. Because the fluctuations can be dramatic (the patient is lucid and conversant in the morning, then confused and drowsy by afternoon), students may anchor on delirium and pursue an infectious or metabolic workup instead of recognizing the chronic, progressive pattern. The vignette will typically include a detail like "these episodes have been occurring for several months" or "the patient's spouse reports intermittent episodes of confusion over the past year," which should redirect you away from delirium.

A third trap is the one-year rule between Lewy body dementia and Parkinson disease dementia. If the stem describes a patient with a five-year history of Parkinson disease who now develops dementia, the answer is Parkinson disease dementia, not Lewy body dementia. The treatments overlap substantially, but the distinction matters for exam purposes.

Finally, remember that REM sleep behavior disorder is a prodromal clue. If a vignette mentions an older man whose wife reports he kicks, punches, or shouts during sleep, and he later develops cognitive decline with hallucinations, this combination should immediately trigger Lewy body dementia as your leading diagnosis. RBD can precede the full clinical syndrome by a decade or more, and it is a powerful discriminator from Alzheimer disease, which does not feature RBD.

The core competency being tested is your ability to recognize the clinical pattern (fluctuation, hallucination, parkinsonism, RBD), link it to the correct diagnosis, and then apply the appropriate management while avoiding a treatment that can cause serious harm.

1e:["$","$L2d",null,{"article":{"id":"827ff645-2699-4c29-8c7c-ae4f6a1f279a","title":"Demensia Badan Lewy","content":"$2e","category":"Neurologi","created_at":"2026-07-29T07:55:59.42448+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]